India’s Zydus Lifesciences is in the FDA’s crosshairs once again, this time for a trio of unnamed violations at an injectables facility. Following an FDA inspection that wrapped up this week, Zydus, ...
Zydus Lifesciences recently received its second Form 483 reprimand from the FDA within the span of one month. In the second write-up, the regulatory agency flagged issues ranging from unqualified ...
Zydus Lifesciences Limited announced on March 11, 2025, that it entered into an agreement to acquire a majority stake in Amplitude Surgical. Reports state that Zydus Lifesciences has a tender offer ...
The acquisition will establish Zydus' presence in fast growing global biologics CDMO space. Acquired capabilities include cutting-edge biologics development and manufacturing services to serve the ...
Zydus receives US FDA final approval for diroximel fumarate delayed-release capsules, 231 mg: Our Bureau, Mumbai Thursday, November 13, 2025, 16:15 Hrs [IST] Zydus Lifesciences Li ...
On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.’s ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...
Aug 9 (Reuters) - Endo International (ENDPQ.PK), opens new tab has sued Zydus Pharmaceuticals (ZYDU.NS), opens new tab in Delaware federal court, claiming Zydus violated its patent rights with a ...
Our Bureau, New Delhi Thursday, November 6, 2025, 15:45 Hrs [IST] Zydus Lifesciences has reported a growth of over 38 per cent i ...
Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis (PBC), clearing the path to a filing to establish the company as a challenger to Gilead Sciences, Intercept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback